Saturday 17 October 2026
Export CYVNY’s income statement to Excel — free account
Ceryvyn Therapeutics Ltd. - Unsponsored ADR
CYVNY Healthcare Biotechnology
Ceryvyn Therapeutics Ltd. - Unsponsored ADR’s revenue for fiscal 2025 (year ended June 2025) was $25,000.00, down 80.0% from fiscal 2024.
0.02
0.00
0.00%
Follow CYVNY
| Jun '25 | Jun '24 | Jun '23 | Jun '22 | Jun '21 | Jun '20 | Jun '19 | Jun '18 | Jun '17 | Jun '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Piotroski F-Score |
3 | 2 | 3 | 3 | — | — | — | — | — | — |
Altman Z-Score |
(30.38) | (6.51) | (8.26) | 4.36 | 60.06 | 54.70 | — | — | — | — |
P/S ratio |
404.91 | 225.61 | 332.48 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(85.09) | (12.83) | (16.86) | (13.18) | 47.03 | 8.04 | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Beneish M-Score |
(3.64) | (3.22) | (4.81) | (6.58) | (2.82) | — | — | — | — | — |
P/Operating CF |
33.87 | 18.87 | 27.81 | 62.58 | 78.87 | 140.86 | — | — | — | — |
P/B ratio |
0.00 | 0.00 | 0.00 | 3.59 | 1.61 | 11.53 | — | — | — | — |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 3.59 | 1.61 | 11.53 | — | — | — | — |
EV/Sales |
1,161.82 | 347.87 | 317.97 | 0.00 | 0.00 | 0.00 | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
EV/Operating CF |
(0.58) | (0.19) | (0.25) | (0.78) | (1.48) | (17.20) | — | — | — | — |
EV/FCF |
(0.58) | (0.19) | (0.25) | (0.79) | (1.48) | (17.20) | — | — | — | — |
Quick Ratio |
0.22 | 2.88 | 5.11 | 4.25 | 39.83 | 10.24 | 5.60 | 5.71 | 27.55 | 8.18 |
Current Ratio |
0.22 | 2.94 | 5.25 | 4.98 | 44.46 | 10.31 | 5.66 | 5.75 | 27.63 | 8.27 |
Net Debt/EBITDA |
0.31 | (0.15) | 0.02 | 0.46 | 2.98 | 2.57 | 0.58 | 1.09 | 5.26 | 1.80 |
Debt/Assets |
0.00% | 106.22% | 86.93% | 0.00% | 0.00% | 0.17% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | (2.65) | (14.65) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.97 | 0.73 | 0.85 | 0.77 | 1.00 | 0.51 | 1.16 | 1.18 | 0.98 | 0.57 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Coverage |
(3.35) | (6.34) | (11.14) | (431.11) | (105.73) | (33.53) | (97.66) | (59.73) | (39.57) | (37.09) |
| 117.59% | 539.40% | (676.68%) | (101.29%) | (50.42%) | (33.54%) | (58.45%) | (35.67%) | (17.96%) | (18.24%) | |
| (132.57%) | (153.25%) | (179.62%) | (93.54%) | (48.28%) | (29.36%) | (48.37%) | (53.49%) | (75.13%) | (17.23%) | |
ROIC |
0.00% | 0.00% | 0.00% | (1,803.34%) | (144.96%) | (517.79%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
80.96% | (177.35%) | (178.87%) | (193.79%) | (33.58%) | (25.10%) | (68.71%) | (45.17%) | (11.60%) | (44.19%) |
Average Days of Receivables |
111,047.60 | 34,526.08 | 22,098.33 | 26,387.05 | 29,467.10 | 37,449.25 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
507,328.00% | 141,060.80% | 118,845.85% | 86,719.07% | 37,743.29% | 20,412.86% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
116,304.00% | 12,622.40% | 19,909.78% | 19,760.09% | 19,533.24% | 7,957.53% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — | — |
Graham Net Nets |
(2.16) | (1.47) | (0.08) | 0.28 | 0.62 | 0.11 | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Earnings Yield |
(13.93%) | (25.00%) | (16.96%) | (3.61%) | (1.94%) | (0.74%) | — | — | — | — |
Free Cash Flow Yield |
(494.89%) | (808.72%) | (378.65%) | (94.23%) | (30.74%) | (5.18%) | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.04) | (2.02) | (2.18) | (1.62) | (1.14) | (0.17) | (0.52) | (0.51) | (0.20) | 0.00 |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(1.04) | (2.02) | (2.18) | (1.62) | (1.12) | (0.16) | (0.52) | (0.51) | (0.20) | 0.00 |
Cash per Share |
0.32 | 2.16 | 1.61 | 1.02 | 2.95 | 1.31 | 0.46 | 0.83 | 1.72 | 0.00 |
Shareholders Equity per Share |
(1.31) | (0.95) | (0.11) | 1.09 | 3.38 | 1.37 | 0.67 | 0.97 | 1.80 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(1.31) | (0.95) | (0.11) | 1.09 | 3.38 | 1.37 | 0.67 | 0.97 | 1.80 | 0.00 |
Free Cash Flow |
(158.66) | (161.05) | (120.63) | (71.35) | (44.89) | (5.36) | (16.91) | (14.77) | (4.65) | (2.74) |
Working Capital |
(201.07) | 124.14 | 79.64 | 47.87 | 135.01 | 44.29 | 21.24 | 27.67 | 41.02 | 10.88 |
Capital Expenditures |
(0.01) | (0.03) | (0.02) | (0.02) | 0.66 | 0.33 | (0.01) | (0.03) | 0.00 | (0.01) |
Net Current Asset Value |
(201.07) | (76.41) | (6.11) | 47.84 | 134.99 | 44.18 | 21.22 | 27.64 | 40.98 | 10.84 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Capex to Sales |
0.52 | 0.26 | 0.20 | 0.19 | (9.57) | (5.64) | — | — | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.61 | 0.42 | 0.42 | 0.34 |
Cash ROIC |
103.95% | (54.19%) | (71.35%) | (77.05%) | (17.71%) | (6.14%) | (45.93%) | (28.21%) | (5.68%) | (12.49%) |
Accounts Receivable Turnover |
0.00 | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 65,015.21 | 91,860.45 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
9.72 | 9.19 | 6.56 | 6.05 | 5.80 | 8.25 | 9.82 | 5.83 | 1.97 | 1.97 |
Average Payables |
23.92 | 28.00 | 14.67 | 6.97 | 3.28 | 4.09 | 4.74 | 4.74 | — | — |
Average Assets |
122.80 | 143.72 | 79.34 | 99.23 | 93.92 | 37.89 | 30.23 | 23.41 | 6.34 | 28.09 |
Average Common Equity |
(138.44) | (40.83) | 21.06 | 91.63 | 89.93 | 33.16 | 25.02 | 35.10 | 26.53 | 26.53 |
Columns are period end dates